Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 7venetoclax 6Azacitidine 6fludarabine 5Cytarabine 4Blood Specimen Collection 4daratumumab 3Lenalidomide 3Daunorubicin 3tislelizumab 2fludarabine phosphate 2Rituximab 2Liquid Biopsy 2Idarubicin 2Gemtuzumab 2Capecitabine 2Busulfan 2trastuzumab deruxtecan 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1tagraxofusp 1sugemalimab 1sacituzumab govitecan 1relugolix 1pembrolizumab 1pegaspargase 1palbociclib 1obinutuzumab 1ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm, Residual × asparaginase erwinia chrysanthemi recombinant × Clear all
NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Baylor College of Medicine

Phase EARLY_PHASE1 Recruiting
36 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡